Tuberc Respir Dis.  2012 Nov;73(5):249-257. 10.4046/trd.2012.73.5.249.

Bronchiectasis

• Kim C
• Kim DG

• KMID: 2050677
• DOI: http://doi.org/10.4046/trd.2012.73.5.249

Abstract

The frequency of diagnosing bronchiectasis is increasing around the world. Cystic fibrosis is the most common inherited cause of bronchiectasis, but there is increasing recognition of significant numbers of patients with bronchiectasis from various causes. With increasing awareness of bronchiectasis, a significant number of research, concerning the causes and treatments, were published over the past few years. Investigation of the underlying cause of bronchiectasis is the most important key to effective management. The purpose of this report is to review the immunological abnormalities that cause bronchiectasis in those that the cystic fibrosis has been excluded, identify the available evidences of current management, and discuss several controversies in the treatment of this disorder.

Keyword

Bronchiectasis; Etiology; Immunologic Deficiency Syndromes; Therapeutics

MeSH Terms

Bronchiectasis
Cystic Fibrosis
Humans
Immunologic Deficiency Syndromes

Reference

1. Goeminne P, Dupont L. Non-cystic fibrosis bronchiectasis: diagnosis and management in 21st century. Postgrad Med J. 2010. 86:493–501.

2. Barker AF, Bardana EJ Jr. Bronchiectasis: update of an orphan disease. Am Rev Respir Dis. 1988. 137:969–978.

3. Seitz AE, Olivier KN, Steiner CA, Montes de Oca R, Holland SM, Prevots DR. Trends and burden of bronchiectasis-associated hospitalizations in the United States, 1993-2006. Chest. 2010. 138:944–949.

4. Roberts HJ, Hubbard R. Trends in bronchiectasis mortality in England and Wales. Respir Med. 2010. 104:981–985.

5. Martínez-García MA, Perpiñá-Tordera M, Román-Sánchez P, Soler-Cataluña JJ. Quality-of-life determinants in patients with clinically stable bronchiectasis. Chest. 2005. 128:739–745.

6. Bilton D. Update on non-cystic fibrosis bronchiectasis. Curr Opin Pulm Med. 2008. 14:595–599.

7. Whitters D, Stockley R. Immunity and bacterial colonisation in bronchiectasis. Thorax. 2012. 67:1006–1013.

8. Li AM, Sonnappa S, Lex C, Wong E, Zacharasiewicz A, Bush A, et al. Non-CF bronchiectasis: does knowing the aetiology lead to changes in management? Eur Respir J. 2005. 26:8–14.

9. Shoemark A, Ozerovitch L, Wilson R. Aetiology in adult patients with bronchiectasis. Respir Med. 2007. 101:1163–1170.

10. Zoumot Z, Wilson R. Respiratory infection in noncystic fibrosis bronchiectasis. Curr Opin Infect Dis. 2010. 23:165–170.

11. O'Donnell AE. Bronchiectasis. Chest. 2008. 134:815–823.

12. Driessen G, van der Burg M. Educational paper: primary antibody deficiencies. Eur J Pediatr. 2011. 170:693–702.

13. Stead A, Douglas JG, Broadfoot CJ, Kaminski ER, Herriot R. Humoral immunity and bronchiectasis. Clin Exp Immunol. 2002. 130:325–330.

14. International Union of Immunological Societies Expert Committee on Primary Immunodeficiencies. Notarangelo LD, Fischer A, Geha RS, Casanova JL, Chapel H, et al. Primary immunodeficiencies: 2009 update. J Allergy Clin Immunol. 2009. 124:1161–1178.

15. Conley ME, Notarangelo LD, Etzioni A. Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies). Clin Immunol. 1999. 93:190–197.

16. Bonilla FA, Bernstein IL, Khan DA, Ballas ZK, Chinen J, Frank MM, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol. 2005. 94:5 Suppl 1. S1–S63.

17. King PT, Hutchinson P, Holmes PW, Freezer NJ, Bennett-Wood V, Robins-Browne R, et al. Assessing immune function in adult bronchiectasis. Clin Exp Immunol. 2006. 144:440–446.

18. De Gracia J, Rodrigo MJ, Morell F, Vendrell M, Miravitlles M, Cruz MJ, et al. IgG subclass deficiencies associated with bronchiectasis. Am J Respir Crit Care Med. 1996. 153:650–655.

19. Kim CH, Kim DG, Park SH, Choi JH, Lee CY, Hwang YI, et al. Incidence of immunoglobulin G subclass deficiencies in patients with bronchiectasis and the clinical characteristics of patients with immunoglobulin G subclass deficiency and bronchiectasis. Tuberc Respir Dis. 2009. 66:295–299.

20. Feldman C. Bronchiectasis: new approaches to diagnosis and management. Clin Chest Med. 2011. 32:535–546.

21. Pasteur MC, Helliwell SM, Houghton SJ, Webb SC, Foweraker JE, Coulden RA, et al. An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med. 2000. 162(4 Pt 1):1277–1284.

22. Sorensen RU, Leiva LE, Javier FC 3rd, Sacerdote DM, Bradford N, Butler B, et al. Influence of age on the response to Streptococcus pneumoniae vaccine in patients with recurrent infections and normal immunoglobulin concentrations. J Allergy Clin Immunol. 1998. 102:215–221.

23. Jeurissen A, Moens L, Raes M, Wuyts G, Willebrords L, Sauer K, et al. Laboratory diagnosis of specific antibody deficiency to pneumococcal capsular polysaccharide antigens. Clin Chem. 2007. 53:505–510.

24. Borgers H, Moens L, Picard C, Jeurissen A, Raes M, Sauer K, et al. Laboratory diagnosis of specific antibody deficiency to pneumococcal capsular polysaccharide antigens by multiplexed bead assay. Clin Immunol. 2010. 134:198–205.

25. Stafler P, Carr SB. Non-cystic fibrosis bronchiectasis: its diagnosis and management. Arch Dis Child Educ Pract Ed. 2010. 95:73–82.

26. Pasteur MC, Bilton D, Hill AT. British Thoracic Society Bronchiectasis Non-CF Guideline Group. British Thoracic Society guideline for non-CF bronchiectasis. Thorax. 2010. 65:Suppl 1. i1–i58.

27. Orange JS, Hossny EM, Weiler CR, Ballow M, Berger M, Bonilla FA, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol. 2006. 117:4 Suppl. S525–S553.

28. Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol. 1999. 92:34–48.

29. Kaveri SV, Maddur MS, Hegde P, Lacroix-Desmazes S, Bayry J. Intravenous immunoglobulins in immunodeficiencies: more than mere replacement therapy. Clin Exp Immunol. 2011. 164:Suppl 2. 2–5.

30. Abrahamian F, Agrawal S, Gupta S. Immunological and clinical profile of adult patients with selective immunoglobulin subclass deficiency: response to intravenous immunoglobulin therapy. Clin Exp Immunol. 2010. 159:344–350.

31. Sheikh A, Nolan D, Greenstone M. Long-acting beta-2-agonists for bronchiectasis. Cochrane Database Syst Rev. 2001. (4):CD002155.

32. Lasserson T, Holt K, Evans D, Greenstone M. Anticholinergic therapy for bronchiectasis. Cochrane Database Syst Rev. 2001. (4):CD002163.

33. Saito Y, Azuma A, Morimoto T, Fujita K, Abe S, Motegi T, et al. Tiotropium ameliorates symptoms in patients with chronic airway mucus hypersecretion which is resistant to macrolide therapy. Intern Med. 2008. 47:585–591.

34. Li XL, Cai SX, Zhao HJ, Dong LM, Shen XB, Liu LY, et al. Therapeutic effect of tiotropium bromide powder inhalation in patients with stable bronchiectasis. Nan Fang Yi Ke Da Xue Xue Bao. 2010. 30:1072–1074.

35. Tsang KW, Tan KC, Ho PL, Ooi GC, Ho JC, Mak J, et al. Inhaled fluticasone in bronchiectasis: a 12 month study. Thorax. 2005. 60:239–243.

36. Martínez-García MA, Perpiñá-Tordera M, Román-Sánchez P, Soler-Cataluña JJ. Inhaled steroids improve quality of life in patients with steady-state bronchiectasis. Respir Med. 2006. 100:1623–1632.

37. Tsang KW, Ho PL, Lam WK, Ip MS, Chan KN, Ho CS, et al. Inhaled fluticasone reduces sputum inflammatory indices in severe bronchiectasis. Am J Respir Crit Care Med. 1998. 158:723–727.

38. Kapur N, Bell S, Kolbe J, Chang AB. Inhaled steroids for bronchiectasis. Cochrane Database Syst Rev. 2009. (1):CD000996.

39. Ducharme FM, Ni Chroinin M, Greenstone I, Lasserson TJ. Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. Cochrane Database Syst Rev. 2010. (5):CD005535.

40. Martínez-García MÁ, Soler-Cataluña JJ, Catalán-Serra P, Román-Sánchez P, Tordera MP. Clinical efficacy and safety of budesonide-formoterol in non-cystic fibrosis bronchiectasis. Chest. 2012. 141:461–468.

41. Cole PJ. Inflammation. A two-edged sword: the model of bronchiectasis. Eur J Respir Dis Suppl. 1986. 147:6–15.

42. Evans DJ, Bara AI, Greenstone M. Prolonged antibiotics for purulent bronchiectasis in children and adults. Cochrane Database Syst Rev. 2007. (2):CD001392.

43. Scheinberg P, Shore E. A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis. Chest. 2005. 127:1420–1426.

44. Murray MP, Govan JR, Doherty CJ, Simpson AJ, Wilkinson TS, Chalmers JD, et al. A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2011. 183:491–499.

45. Rubin BK. Aerosolized antibiotics for non-cystic fibrosis bronchiectasis. J Aerosol Med Pulm Drug Deliv. 2008. 21:71–76.

46. Friedlander AL, Albert RK. Chronic macrolide therapy in inflammatory airways diseases. Chest. 2010. 138:1202–1212.

47. Crosbie PA, Woodhead MA. Long-term macrolide therapy in chronic inflammatory airway diseases. Eur Respir J. 2009. 33:171–181.

48. Griffith DE, Brown-Elliott BA, Langsjoen B, Zhang Y, Pan X, Girard W, et al. Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2006. 174:928–934.

49. Altenburg J, de Graaff CS, van der Werf TS, Boersma WG. Immunomodulatory effects of macrolide antibiotics - part 2: advantages and disadvantages of long-term, low-dose macrolide therapy. Respiration. 2011. 81:75–87.

50. King P. Is there a role for inhaled corticosteroids and macrolide therapy in bronchiectasis? Drugs. 2007. 67:965–974.

51. Poole PJ, Black PN. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2006. (3):CD001287.

52. Crisafulli E, Coletti O, Costi S, Zanasi E, Lorenzi C, Lucic S, et al. Effectiveness of erdosteine in elderly patients with bronchiectasis and hypersecretion: a 15-day, prospective, parallel, open-label, pilot study. Clin Ther. 2007. 29:2001–2009.

53. Daviskas E, Anderson SD, Eberl S, Chan HK, Bautovich G. Inhalation of dry powder mannitol improves clearance of mucus in patients with bronchiectasis. Am J Respir Crit Care Med. 1999. 159:1843–1848.

54. Wills P, Greenstone M. Inhaled hyperosmolar agents for bronchiectasis. Cochrane Database Syst Rev. 2006. (2):CD002996.

55. Gjoerup J, Hilberg O, Bendstrup E. Inhaled mannitol in the treatment of non-cystic fibrosis bronchiectasis in adults. Respirology. 2012. 17:927–932.

56. King PT, Daviskas E. Management of bronchiectasis. Breathe. 2010. 6:353–360.

57. Murray MP, Pentland JL, Hill AT. A randomised crossover trial of chest physiotherapy in non-cystic fibrosis bronchiectasis. Eur Respir J. 2009. 34:1086–1092.

58. Jones AP, Rowe BH. Bronchopulmonary hygiene physical therapy for chronic obstructive pulmonary disease and bronchiectasis. Cochrane Database Syst Rev. 2000. (2):CD000045.

59. Chang CC, Morris PS, Chang AB. Influenza vaccine for children and adults with bronchiectasis. Cochrane Database Syst Rev. 2007. (3):CD006218.

60. Chang CC, Singleton RJ, Morris PS, Chang AB. Pneumococcal vaccines for children and adults with bronchiectasis. Cochrane Database Syst Rev. 2009. (2):CD006316.

61. Furumoto A, Ohkusa Y, Chen M, Kawakami K, Masaki H, Sueyasu Y, et al. Additive effect of pneumococcal vaccine and influenza vaccine on acute exacerbation in patients with chronic lung disease. Vaccine. 2008. 26:4284–4289.

62. Sorensen RU, Leiva LE, Giangrosso PA, Butler B, Javier FC 3rd, Sacerdote DM, et al. Response to a heptavalent conjugate Streptococcus pneumoniae vaccine in children with recurrent infections who are unresponsive to the polysaccharide vaccine. Pediatr Infect Dis J. 1998. 17:685–691.